The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone

Cancer Cell

Volumn 27, Issue 6, 2015, Pages 809-821

  Fournier, Pierrick G J ^a,b   Juárez, Patricia ^a,b   Jiang, Guanglong ^a   Clines, Gregory A ^b,c   Niewolna, Maria ^a,b   Kim, Hun Soo ^a   Walton, Holly W ^b   Peng, Xiang Hong ^a,b   Liu, Yunlong ^a   Mohammad, Khalid S ^a,b   Wells, Clark D ^a   Chirgwin, John M ^a,b,d   Guise, Theresa A ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM19 PROTEIN; COL1A1 PROTEIN; COLLAGENASE 3; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN D1; DICKKOPF 1 PROTEIN; INTERLEUKIN 11; NEDD9 PROTEIN; PMEPA1 PROTEIN; PROTEIN; SMAD2 PROTEIN; THBS1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN A; MEMBRANE PROTEIN; PMEPA1 PROTEIN, HUMAN; PTERIDINE DERIVATIVE; SD-208;

ANIMAL CELL; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CELL CYCLE REGULATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MALE; METASTASIS FREE SURVIVAL; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DISEASE MODEL; GENETICS; HEPG2 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PTERIDINES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84930573987     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.04.009     Document Type: Article

References (54)

1. Carstens J.L., Shahi P., Van Tsang S., Smith B., Creighton C.J., Zhang Y., Seamans A., Seethammagari M., Vedula I., Levitt J.M., et al. FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014, 74:609-620.
2. Chandran U.R., Ma C., Dhir R., Bisceglia M., Lyons-Weiler M., Liang W., Michalopoulos G., Becich M., Monzon F.A. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7:64.
3. Chesneau V., Becherer J.D., Zheng Y., Erdjument-Bromage H., Tempst P., Blobel C.P. Catalytic properties of ADAM19. J.Biol. Chem. 2003, 278:22331-22340.
4. Clines G.A., Mohammad K.S., Bao Y., Stephens O.W., Suva L.J., Shaughnessy J.D., Fox J.W., Chirgwin J.M., Guise T.A. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol. Endocrinol. 2007, 21:486-498.
5. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M., Lawler J., Hynes R.O., Boivin G.P., Bouck N. Thrombospondin-1 is a major activator of TGF-β1 invivo. Cell 1998, 93:1159-1170.
6. Crippa M.P. Urokinase-type plasminogen activator. Int. J. Biochem. Cell Biol. 2007, 39:690-694.
7. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998, 17:3091-3100.
8. Dunn L.K., Mohammad K.S., Fournier P.G., McKenna C.R., Davis H.W., Niewolna M., Peng X.H., Chirgwin J.M., Guise T.A. Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 2009, 4:e6896.
9. Garber M.E., Troyanskaya O.G., Schluens K., Petersen S., Thaesler Z., Pacyna-Gengelbach M., van de Rijn M., Rosen G.D., Perou C.M., Whyte R.I., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 2001, 98:13784-13789.
10. Goswami C.P., Nakshatri H. PROGgene: gene expression based survival analysis web application for multiple cancers. J.Clin. Bioinforma. 2013, 3:22.
11. Gulzar Z.G., McKenney J.K., Brooks J.D. Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1. Oncogene 2013, 32:70-77.
12. Hall C.L., Zhang H., Baile S., Ljungman M., Kuhstoss S., Keller E.T. p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res. 2010, 70:9916-9926.
13. Hu Z., Gupta J., Zhang Z., Gerseny H., Berg A., Chen Y.J., Zhang Z., Du H., Brendler C.B., Xiao X., et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum. Gene Ther. 2012, 23:871-882.
14. Ivshina A.V., George J., Senko O., Mow B., Putti T.C., Smeds J., Lindahl T., Pawitan Y., Hall P., Nordgren H., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66:10292-10301.
15. Javelaud D., Mohammad K.S., McKenna C.R., Fournier P., Luciani F., Niewolna M., André J., Delmas V., Larue L., Guise T.A., Mauviel A. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res. 2007, 67:2317-2324.
16. Juárez P., Guise T.A. TGF-β in cancer and bone: implications for treatment of bone metastases. Bone 2011, 48:23-29.
17. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordón-Cardo C., Guise T.A., Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
18. Kang Y., He W., Tulley S., Gupta G.P., Serganova I., Chen C.R., Manova-Todorova K., Blasberg R., Gerald W.L., Massagué J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA 2005, 102:13909-13914.
19. Koeneman K.S., Yeung F., Chung L.W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39:246-261.
20. Korpal M., Yan J., Lu X., Xu S., Lerit D.A., Kang Y. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 2009, 15:960-966.
21. Kudo Y., Iizuka S., Yoshida M., Tsunematsu T., Kondo T., Subarnbhesaj A., Deraz E.M., Siriwardena S.B., Tahara H., Ishimaru N., et al. Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis. J.Biol. Chem. 2012, 287:38716-38728.
22. Lallemand F., Seo S.R., Ferrand N., Pessah M., L'Hoste S., Rawadi G., Roman-Roman S., Camonis J., Atfi A. AIP4 restricts transforming growth factor-β signaling through a ubiquitination-independent mechanism. J.Biol. Chem. 2005, 280:27645-27653.
23. Li H., Xu L.L., Masuda K., Raymundo E., McLeod D.G., Dobi A., Srivastava S. A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J.Biol. Chem. 2008, 283:28988-28995.
24. Loi S., Haibe-Kains B., Desmedt C., Lallemand F., Tutt A.M., Gillet C., Ellis P., Harris A., Bergh J., Foekens J.A., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J.Clin. Oncol. 2007, 25:1239-1246.
25. Ma X.J., Dahiya S., Richardson E., Erlander M., Sgroi D.C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009, 11:R7.
26. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102:13550-13555.
27. Miyake H., Pollak M., Gleave M.E. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. 2000, 60:3058-3064.
28. Mohammad K.S., Chen C.G., Balooch G., Stebbins E., McKenna C.R., Davis H., Niewolna M., Peng X.H., Nguyen D.H., Ionova-Martin S.S., et al. Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 2009, 4:e5275.
29. Mohammad K.S., Javelaud D., Fournier P.G., Niewolna M., McKenna C.R., Peng X.H., Duong V., Dunn L.K., Mauviel A., Guise T.A. TGF-β-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 2011, 71:175-184.
30. Morimoto K., Tanaka T., Nitta Y., Ohnishi K., Kawashima H., Nakatani T. NEDD9 crucially regulates TGF-β-triggered epithelial-mesenchymal transition and cell invasion in prostate cancer cells: involvement in cancer progressiveness. Prostate 2014, 74:901-910.
31. Pécheur I., Peyruchaud O., Serre C.M., Guglielmi J., Voland C., Bourre F., Margue C., Cohen-Solal M., Buffet A., Kieffer N., Clézardin P. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. 2002, 16:1266-1268.
32. Pickup M., Novitskiy S., Moses H.L. The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer 2013, 13:788-799.
33. Roberts E., Cossigny D.A., Quan G.M. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer 2013, 2013:418340.
34. Schmidt M., Asirvatham A.J., Chaudhary J. Inhibitor of differentiation 1 (ID1) promotes cell survival and proliferation of prostate epithelial cells. Cell. Mol. Biol. Lett. 2010, 15:272-295.
35. Schwarze S.R., DePrimo S.E., Grabert L.M., Fu V.C., Brooks J.D., Jarrard D.F. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J.Biol. Chem. 2002, 277:14877-14883.
36. Sethi N., Dai X., Winter C.G., Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19:192-205.
37. Shah M., Huang D., Blick T., Connor A., Reiter L.A., Hardink J.R., Lynch C.C., Waltham M., Thompson E.W. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS ONE 2012, 7:e29615.
38. Sharad S., Ravindranath L., Haffner M.C., Li H., Yan W., Sesterhenn I.A., Chen Y., Ali A., Srinivasan A., McLeod D.G., et al. Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer. Epigenetics 2014, 9:918-927.
39. Shi Y., Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
40. Shimo T., Kubota S., Yoshioka N., Ibaragi S., Isowa S., Eguchi T., Sasaki A., Takigawa M. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J.Bone Miner. Res. 2006, 21:1045-1059.
41. Stankic M., Pavlovic S., Chin Y., Brogi E., Padua D., Norton L., Massagué J., Benezra R. TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep. 2013, 5:1228-1242.
42. Tang L.Y., Yamashita M., Coussens N.P., Tang Y., Wang X., Li C., Deng C.X., Cheng S.Y., Zhang Y.E. Ablation of Smurf2 reveals aninhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3. EMBO J. 2011, 30:4777-4789.
43. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
44. Uhl M., Aulwurm S., Wischhusen J., Weiler M., Ma J.Y., Almirez R., Mangadu R., Liu Y.W., Platten M., Herrlinger U., et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells invitro and invivo. Cancer Res. 2004, 64:7954-7961.
45. Vanaja D.K., Cheville J.C., Iturria S.J., Young C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003, 63:3877-3882.
46. Vo Nguyen T.T., Watanabe Y., Shiba A., Noguchi M., Itoh S., Kato M. TMEPAI/PMEPA1 enhances tumorigenic activities in lung cancer cells. Cancer Sci. 2014, 105:334-341.
47. Wan X., Li Z.G., Yingling J.M., Yang J., Starbuck M.W., Ravoori M.K., Kundra V., Vazquez E., Navone N.M. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth. Bone 2012, 50:695-703.
48. Watanabe Y., Itoh S., Goto T., Ohnishi E., Inamitsu M., Itoh F., Satoh K., Wiercinska E., Yang W., Shi L., et al. TMEPAI, a transmembrane TGF-β-inducible protein, sequesters Smad proteins from active participation in TGF-β signaling. Mol. Cell 2010, 37:123-134.
49. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 2011, 11:411-425.
50. Xu L.L., Shanmugam N., Segawa T., Sesterhenn I.A., McLeod D.G., Moul J.W., Srivastava S. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 2000, 66:257-263.
51. Xu L.L., Shi Y., Petrovics G., Sun C., Makarem M., Zhang W., Sesterhenn I.A., McLeod D.G., Sun L., Moul J.W., Srivastava S. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res. 2003, 63:4299-4304.
52. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., Massagué J., Mundy G.R., Guise T.A. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J.Clin. Invest. 1999, 103:197-206.
53. Zhang Y., Chang C., Gehling D.J., Hemmati-Brivanlou A., Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. USA 2001, 98:974-979.
54. Zhang X.H., Wang Q., Gerald W., Hudis C.A., Norton L., Smid M., Foekens J.A., Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.